Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide.
We have determined the crystal structures of the ligand binding domain (LBD) of the rat vitamin D receptor in ternary complexes with a synthetic LXXLL-containing peptide and the following four ligands: 1alpha,25-dihydroxyvitamin D(3); 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) (2MD); 1alpha-hydroxy-2-methylene-19-nor-(20S)-bishomopregnacalciferol (2MbisP), and 2alpha-methyl-19-nor-1alpha,25-dihydroxyvitamin D(3) (2AM20R). The conformation of the LBD is identical in each complex. Binding of the 2-carbon-modified analogues does not change the positions of the amino acids in the ligand binding site and has no effect on the interactions in the coactivator binding pocket. The CD ring of the superpotent analogue, 2MD, is tilted within the binding site relative to the other ligands in this study and to (20S)-1alpha,25-dihydroxyvitamin D(3) [Tocchini-Valentini et al. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 5491-5496]. The aliphatic side chain of 2MD follows a different path within the binding site; nevertheless, the 25-hydroxyl group at the end of the chain occupies the same position as that of the natural ligand, and the hydrogen bonds with histidines 301 and 393 are maintained. 2MbisP binds to the receptor despite the absence of the 25-hydroxyl group. A water molecule is observed between His 301 and His 393 in this structure, and it preserves the orientation of the histidines in the binding site. Although the alpha-chair conformer is highly favored in solution for the A ring of 2AM20R, the crystal structures demonstrate that this ring assumes the beta-chair conformation in all cases, and the 1alpha-hydroxyl group is equatorial. The peptide folds as a helix and is anchored through hydrogen bonds to a surface groove formed by helices 3, 4, and 12. Electrostatic and hydrophobic interactions between the peptide and the LBD stabilize the active receptor conformation. This stablization appears necessary for crystal growth.
Vanhooke
Janeen L
JL
Department of Biochemistry, University of Wisconsin-Madison, 53711, USA. jlvanhoo@wisc.edu
Benning
Matthew M
MM
Bauer
Cary B
CB
Pike
J Wesley
JW
DeLuca
Hector F
HF
D020816:Amino Acid Motifs; D000818:Animals; D001665:Binding Sites; D002117:Calcitriol / Q000031:analogs & derivatives* / Q000378:metabolism; D002762:Cholecalciferol / Q000031:analogs & derivatives* / Q000737:chemistry*; D018360:Crystallography, X-Ray; D004100:Dihydroxycholecalciferols / Q000378:metabolism; D008024:Ligands; D046911:Macromolecular Substances; D056913:Mediator Complex Subunit 1; D008968:Molecular Conformation; D010455:Peptides / Q000737:chemistry*; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D051381:Rats; D018167:Receptors, Calcitriol / Q000737:chemistry* / Q000378:metabolism*; D015534:Trans-Activators / Q000737:chemistry*; D014157:Transcription Factors / Q000737:chemistry*
C468519:2-methylene-1,25-dihydroxy-19-norvitamin D3; D004100:Dihydroxycholecalciferols; D008024:Ligands; D046911:Macromolecular Substances; C538857:Med1 protein, rat; D056913:Mediator Complex Subunit 1; D010455:Peptides; D018167:Receptors, Calcitriol; D015534:Trans-Activators; D014157:Transcription Factors; D002762:Cholecalciferol; C011484:1-hydroxypregnacalciferol; D002117:Calcitriol